QIMR Berghofer researchers have discovered a potential new cancer immunotherapy target that involves switching off a regulatory cell to stop tumours growing and spreading.
The study findings have been published today in Cancer Discovery, a journal of the American Association for Cancer Research.
Senior researcher and head of QIMR Berghofer’s Cancer Immunoregulation and Immunotherapy Laboratory, Associate Professor Michele Teng, said in future the discovery could potentially help treat patients with cancers where other current immunotherapies have not worked.
“Our work on mice shows for the first time that many tumours display the molecule MR1 on their cell surface, and when it’s present, this molecule turns on an important regulatory cell that prevents the body’s own immune system from fighting the cancer,” Associate Professor Teng said.
“We found if a type of regulatory cell called MAIT (mucosal-associated invariant T) cells are turned on, they stop immune or white blood cells known as T and NK cells from attacking and killing off tumour cells.
“The cancer is effectively creating its own defence mechanism to evade immune attack and survive. The display of MR1 activates the MAIT cells, which in turn switch off cancer-fighting T and NK cells.
“While other regulatory cells of the immune system are known to stop T and NK cells from killing tumour cells, this is the first time it’s been shown that these regulatory MAIT cells can do this job.”
Associate Professor Teng said her team found that by giving mice an antibody that blocked MR1, this stopped the MAIT cells from becoming activated, and the T and NK cells could respond, slowing cancer growth and stopping it spreading.
“This work demonstrates that antibodies that block MR1 could in future be an effective new immunotherapy,” Associate Professor Teng said.
“It probably won’t work on every cancer, but it looks like it could be effective in treating cancers that can display the MR1 molecule. It also means this display of MR1 could be used to screen which patients would respond to this immunotherapy.
“We now need to replicate this research in humans.”
Associate Professor Teng said while the research was at a very early stage and required more work, it was promising.
“The next step is to try to understand what kind of human tumours display MR1 as a protective mechanism, which would then help us identify which tumours would respond best to MR1-blocking immunotherapy,” she said.
“Immunotherapies have been effectively used to treat more than 15 different cancer types but the proportion of patients that respond for each cancer can differ.
“In patients with advanced melanoma for example, current approved immunotherapies work in about 50 per cent of cases, but half do not respond, and that’s why we need to find new therapies.”
Learn more: POTENTIAL NEW CANCER TREATMENT A STEP CLOSER
Go deeper with Bing News on:
- Real-World Patients May Have More Side Effects to Immunotherapy for Lung Cancer Compared With Clinical Trial Dataon January 20, 2021 at 11:24 am
Findings from a study focused on patient-reported experiences, found that aching joints, aching muscles and fatigue were more common than initially found in clinical trials.
- GSK/Merck & Co’s hopeful bintrafusp alfa fails in key lung cancer trialon January 20, 2021 at 9:04 am
GlaxoSmithKline’s big gamble on a cancer drug developed by Germany’s Merck KGaA looks unlikely to pay out, after bintrafusp alfa failed to outperform US-based Merck & Co’s Keytruda in a lung cancer ...
- NEUVOGEN Announces Next Generation Cancer Vaccine Strategy to Transform how Solid Tumors are Treatedon January 20, 2021 at 4:42 am
NEUVOGEN, an immunoncology company, announces its novel cancer vaccine strategy to transform how solid tumors are treated. NEUVOGEN's stra ...
- US Breast Cancer Drug Antibodies Immunotherapy Therapeutics Market Offers USD 20 Billion Opportunity by 2026on January 20, 2021 at 2:59 am
DELHI, India, (GLOBE NEWSWIRE) -- "US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights: US breast cancer market has experienced advancements in the ...
- Immunotherapy biotech NexImmune files for an $86 million IPOon January 19, 2021 at 1:42 pm
N exImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering. NexImmune is developing a novel ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Merck Announces Update on the [email protected] Clinical Program Including Lung 037 Studyon January 20, 2021 at 7:48 am
PRNewswire/ -- Not intended for US-, Canada- or UK-based mediaMerck, a leading science and technology company, ...
- Merck KGaA, Darmstadt, Germany Announces Update on the [email protected] Clinical Program Including Lung 037 Studyon January 20, 2021 at 7:17 am
PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced an update on the Phase III [email protected] Lung 037 study and the ...
- Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to ...on January 19, 2021 at 10:08 pm
Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease. NOVA awarded €2.4 millionto lever ...
- Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host diseaseon January 19, 2021 at 12:30 am
Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease NOVA awarded €2.4 million ...
- Immunotherapy Veteran Robert Knight, MD, Joins NexImmune as Chief Medical Officeron January 18, 2021 at 6:17 pm
With more than 25 years of clinical development leadership experience at companies such as Celgene and Kite Pharmaceuticals, Dr. Knight will now lead the clinical development of NexImmune’s novel ...